ACE and dilated cardiomyopathy: Specifically, Houde et al. [23] found the proportion of participants with dilated cardiomyopathy (defined as FS < 28% or LVEDD > 95th percentile) to be lower among those treated with deflazacort (in some cases in combination with ACE inhibitors [agents not reported]) than those who were untreated (32% vs. 58%, p < 0.05).